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Abstract:
Study Design Nineteen dogs underwent L4-L5 intertransverse process fusions with either 58 μg, 115
μg, 230 μg, 460 μg, or 920 μg of recombinant human bone morphogenetic protein-2 carried by a
polylactic acid polymer. A previous study (12 dogs) compared 2300 μg of recombinant human bone
morphogenetic protein-2, autogenous iliac bone, and carrier alone in this model. All fusions
subsequently were compared.
Objectives: To characterize the dose-response relationship of recombinant human bone
morphogenetic protein-2 in a spinal fusion model.
Summary of Background Data: Recombinant osteoinductive morphogens, such as recombinant human
bone morphogenetic protein-2, are effective in vertebrate diaphyseal defect and spinal fusion models.
It is hypothesized that the quality of spinal fusion produced with recombinant human bone
morphogenetic protein-2, above a threshold dose, does not change with increasing amounts of
inductive protein.
Methods: After decortication of the posterior elements, the designated implants were placed along the
intertransverse process space bilaterally. The fusion sites were evaluated after 3 months by computed
tomography imaging, high-resolution radiography, manual testing, mechanical testing, and histologic
analysis.
Results: As in the study using 2300 μg of recombinant human bone morphogenetic protein-2,
implantation of 58–920 μg of recombinant human bone morphogenetic protein-2 successfully resulted
in intertransverse process fusion in the dog by 3 months. This had not occurred in animals containing
autograft or carrier alone. The cross-sectional area of the fusion mass and mechanical stiffness of the
L4-L5 intersegment were not dose-dependent. Histologic findings varied but were not related to

rhBMP-2 dose. Inflammatory reaction to the composite implant was proportional inversely to the
volume of the fusion mass.
Conclusions: No mechanical, radiographic, or histologic differences in the quality of intertransverse
process fusion resulted from a 40-fold variation in dose of recombinant human bone morphogenetic
protein-2.
Recombinantly produced osteoinductive molecules, such as human bone morphogenetic protein, have
facilitated healing of middiaphysial defects and fusion of spinal segments in lower vertebrates. Doses
of recombinant bone morphogenetic proteins ranging from 1.4 μg to more than 2000 μg have been
tested in experimentally produced segmental long bone defects in rodents, rabbits, sheep, and
dogs.3,5,6,8,9,17,25 A recent study using recombinant human bone morphogenetic protein-7 (rhBMP-7) in
a rabbit ulnar nonunion model suggested that greater amounts of implanted protein resulted in
greater early bone formation and a faster rate of healing.5 However, radiographic findings by 8 weeks
and histologic results by 12 weeks were similar in all ulnar defects implanted with doses above a
threshold of 6.25 μg. All of these defects healed successfully, whereas ulnae implanted with less than
the threshold amount of inductive protein failed to do so.
The relationship between BMP dose and the rate and character of intersegmental spinal fusion has not
been well defined. The purpose of this investigation was to evaluate fusion characteristics associated
with a logarithmic series of doses of recombinant human bone morphogenetic protein-2 (rhBMP-2)
delivered by a porous polylactic acid polymer in a dog lumbar intertransverse process fusion model. A
previous study at this institution showed that a dose of 2300 μg of rhBMP-2 delivered by the same
carrier was superior to autologous iliac crest bone graft for producing single-level lumbar arthrodesis.16
Data from that study are included here for purposes of comparison.

▪ Materials and Methods
Design. Nineteen mature female beagles underwent L4-L5 intertransverse process fusions in this study
(Table 1). Five doses of rhBMP-2 in a modified logarithmic schedule were tested. In a previous study
with this model, five dogs were implanted with autogenous iliac crest graft, five were implanted with a
2300 μg dose of rhBMP-2, and two were implanted with the carrier alone. The results from that study
are included here for comparison. Neither internal fixation nor external immobilization was used in
either investigation. All animals were killed 3 months after surgery.

Table 1
Materials. The delivery vehicle open cell polylactic acid (OPLA) was prepared from D,D-L,L-polylactic
acid and macrostructured into an “open cell” network of interconnected voids. The dimensions of this
2.2-mL rectangular strip were 12.0 mm × 6.0 mm × 30.0 mm (supplied by Sofamor Danek, Memphis,
TN; developed and manufactured by THM Biomedical, Minneapolis, MN).
The rhBMP-2 (manufactured and supplied by Genetics Institute, Andover, MA) was provided in freezedried form and reconstituted intraoperatively with sterile water. One milliliter of solution containing 58
μg, 115 μg, 230 μg, 460 μg, or 920 μg of rhBMP-2 was added to each OPLA strip to produce the
composite implant.
Subjects. The animals were obtained from a single breeder and screened for systemic disease and
conditioned for at least 1 week before inclusion in the study.
Surgical Procedure. Under halothane anesthesia and endotracheal intubation, the posterior lumbar
region was prepared in sterile fashion. Using a limited midline approach, the paraspinal musculature
was retracted from the spinous processes, lamina, facet joints, and transverse processes. With the
assistance of a localization radiograph, care was taken to avoid exposure of adjacent facet joints and
transverse processes. The appropriate transverse processes, lamina, and facet joints were decorticated
with a power burr (Dremel Moto- Tool, Model 395, Racine, WI) until punctate bleeding was observed.
Osseous debris left by decortication was washed away thoroughly with copious irrigation.

The composite implant was prepared by the surgical assistant and inserted by the surgeon, who was
blinded to the condition of the implant. When autograft was used, tricortical portions of both iliac
crests were harvested through the same incision and morselized to expose the cancellous surfaces. All
implants were placed into the right and left posterolateral gutters in direct apposition to the
decorticated transverse processes of L4 and L5. The implants were not in contact with the exposed
lamina.
Routine closure of the dorsolumbar fascia, subcutaneous tissue, and skin was performed. Parenteral
antibiotics (enrofloxacin, 2.5 mg/kg, or cefazolin, 2.0 mg/kg) were administered intraoperatively and
postoperatively for 72 hours after surgery. No postoperative dressings or braces were applied. The
animals were allowed unrestricted activity.
Computed Tomography Evaluation. With the animals under pentobarbital anesthesia (Nembutal,
Abbott, Abbott Park, IL), computed tomography (CT) scans were obtained 2 and 3 months after surgery
for all animals. Sections of the fusion site were graded qualitatively for bone formation and
remodeling. Also, quantitative CT analysis was performed using a photo image analyzer (superfine
pitch monitor, Image-1/AT software, University Imaging Corp., West Chester, PA) as follows: crosssectional bone area was measured in four specific axial images of the fusion site and in four
anatomically matched axial images of the untreated L3 vertebral body. The axial images were selected
based on known vertebral body landmarks consistently present in beagles. Estimation of new bone
formation was accomplished by measuring the difference in cross-sectional bone area between images
of the fusion site and images of anatomically corresponding sections of the L3 vertebral body
(reference measures). The values were expressed as ratios to these reference measures.
Sacrifice. Three months after surgery, the animals were killed with 0.22 mL/kg of Euth-6 Veterinary
Solution (Western Medical Supply Company, Arcadia, CA), and the lumbar spines were explanted.
Manual Testing. After explantation, the L4-L5 intervertebral segment was tested manually for motion.
The intervertebral segment was graded a nonfusion if motion was detected in any plane. Absence of
motion was considered sufficient evidence of fusion.
High-Resolution Radiographic Evaluation. Using the Faxitron imaging device (Field Emission
Corporation, McMinnville, Oregon), a high-resolution radiograph was taken of the explanted lumbar
spine in the coronal plane after cleaning of soft tissues (Kodak Industrex Film, 50 - 13 × 18 cm, #507–
2392, exposure ≈30 MA @ 3 minutes). A radiographically successful intertransverse process fusion was
defined as complete and uninterrupted osseous bridging of the transverse processes bilaterally.
Unilateral osseous bridging or facet or interlaminar bony union was not considered successful
intertransverse process fusion.
Nondestructive Mechanical Testing. The mechanical tests were conducted on all but one specimen
from each rhBMP-2 dose group. The testing consisted of manually applying pure torques and linear
loads and then measuring the corresponding angular and linear displacements. The slope of the forcedisplacement curve at 45 N of applied force was used to calculate the stiffness in each mode. The
measurements were conducted in the following modes: flexion-extension (sagittal plane), right and left

lateral bending (coronal plane), and clockwise and counterclockwise rotation (axial plane). For each
mode, the average of the median measures of stiffness for the two directions was used for analysis.
The protocol for this testing has been described previously.16
Histologic Analysis. After mechanical testing, the spinal motion segment was fixed in 10% neutral
buffered formaldehyde solution and bisected sagittally for histologic analysis. Both halves of the spinal
segment were dehydrated sequentially in 70% alcohol for 2–3 days, 95% alcohol for 2–3 days, two
changes of 100% alcohol for 2–3 days each, and xylene for 1 day.
The explants then were embedded in methylmethacrylate and sectioned on a diamond saw (Buehler
Isomet, Lake Bluff, IL) to produce at least 10 sections of an approximate thickness of 100–200 μm. One
side of the bisected level was sectioned in the sagittal plane, whereas the other side was sectioned in
the axial plane. This orientation was randomized.
Undeclacified sections of the explants from this study were imaged with copper k-α-radiation at 20 kV
and 30 mA using a microradiography unit (Kristalloflex-2, Siemens, New York, NY) and spectroscopic
film (Kodak, Rochester, NY). Sections were exposed for 12.5 minutes for each 100 μm of thickness.
These spectroscopic plates then were developed, fixed, and analyzed for ossification using standard
optical microscopy.
Staining was performed after microradiography to determine the quality and quantity of osteogenesis.
When de novo bone was present, the distinct histogenesis (e.g., enchondral or intramembranous
osteogenesis) was noted as was the presence of woven or lamellar bone matrix. Finally, differential
staining with basic fuchsin and toluidine blue-o was used to evaluate the histologic and cytologic host
response to the implant. This included evaluating the presence or absence of an inflammatory
response to the carrier, the amount and quality of bone present, and the interface between the new
bone and the native host bone. After staining, all undecalcified sections and microradiographs were
read by an orthopedic histopathologist in a blinded fashion.
Statistical Analysis. Qualitative manual testing data, radiographic data, and CT data were analyzed
using Fisher's exact test. Analysis of variance (BMDP Statistical Software, 2 V, Los Angeles, CA) was
applied to measures of stiffness. Group average stiffness was compared among rhBMP-2 doses (high
vs. low) separately for each mode of motion: sagittal bending, coronal bending, and axial rotation.
There was one grouping factor (dose of rhBMP-2). Pearson's correlation coefficient was used to
characterize the relationships between variables of interest and dose of rhBMP-2. Logistic regression
analysis was used to evaluate the relationship between radiographic fusion and dose of rhBMP-2 (SAS,
Version 6, SAS Institute Inc., Cary, NC).

Results
Surgery
All animals tolerated the procedures well, and no perioperative deaths occurred. Postoperative
infections developed in two dogs that had been implanted with 58 μg of rhBMP-2, so they were

excluded from the study. The dogs weighed between 8.60–12.50 kg (average, 10.49 kg) and ranged in
age from 1.09 to 2.28 years (mean age, 1.59 years) at the time of surgery.
Computed Tomography
Computed tomography images showed new bone formation at all sites implanted with rhBMP-2 by 2
months after surgery (Figure 1). There was scant evidence of peripheral cortices surrounding the fusion
masses in any site by this time. There were no remarkable qualitative differences between specimens
containing different doses of the inductive protein.

Figure 1
By 3 months, the presence of peripheral cortices was noted in several rhBMP-2 implanted sites (Figure
2). This remodeling was not related to the dose of the inductive protein.

Figure 2
Quantitative CT analysis measuring new bone formation was performed on all fusion sites containing
rhBMP-2. The findings are summarized in Table 2 and include data from the previous study. There
were no differences in cross-sectional area of new bone regardless of the dose of rhBMP-2 implanted
(P = 0.84).

Table 2
High-Resolution Radiography
Using the strict criteria for fusion described previously, radiographic fusion rates are depicted in Table
3. In the rhBMP-2 implanted sites, 14 (82%) of 17 sites in the current study were fused
radiographically. Two failures were noted in the lowest two dose groups (58 μg and 115 μg) and the
third was in an intermediate group (460 μg). All three of these spines actually were unilateral fusions
but, according to the rating criteria, were considered failures. Using logistic regression analysis,
however, no relationship was found between rhBMP-2 dose and radiographic fusion (P = 0.55; n = 17).
Examples of highresolution radiographs of spines containing rhBMP-2 implants can be seen in Figure 3.

Table 3

Figure 3

Manual Testing
All spines implanted with rhBMP-2 composites, regardless of dose, achieved solid intersegmental
fusion by manual motion testing (Table 4). No differences could be detected among rhBMP-2implanted sites.

Table 4
Mechanical Testing
Mechanical testing was performed on all specimens regardless of the presence or absence of
intertransverse process bridging. This was done to incorporate effects of facet arthrodesis that have
been reported in dog models after decortication.4 Median values for stiffness for each mode of testing
were compared. There were no significant differences in mechanical stiffness among the dose groups
of rhBMP-2 (sagittal bending, P = 0.38; coronal bending, P = 0.34; axial torque, P = 0.42). There was no
correlation between dose and stiffness of fusion in any of the three planes of motion (sagittal bending,
P = 0.99; coronal bending, P = 0.45; axial torque, P = 0.39).
Histologic Examination
Several specimens that had been implanted with the rhBMP-2 and OPLA carrier composite exhibited
remnants of the polymeric delivery vehicle (Figure 4). The amount of undegraded polymer was not
related to the dose of rhBMP-2 that was used. There appeared to be no relationship between the
degree of inflammatory response and the dose of rhBMP-2. However, when abundant bone formation
and a large fusion mass occurred, little to no inflammatory response was observed. When a large

fusion mass did not occur, a low grade chronic inflammatory response consisting of multinucleated
giant cells and round cells was observed.

Figure 4
Varying quantities of de novo bone were noted in all specimens containing rhBMP-2 (Figure 5). Grossly
and microscopically, no intrusion of de novo bone was noted in the spinal canal. Lamellar and woven
bone trabeculae were seen with scattered areas of cortical remodeling. The overall amount of de novo
bone, the ratio of lamellar to woven bone, and the degree of cortical remodeling could not be
correlated with the dose of rhBMP-2. There was as much qualitative difference in bone formation
between animals containing the same dose as there was between animals containing different doses.

Figure 5

▪ Discussion
Bone morphogenetic protein constitutes less than 0.01% of total bone protein and less than 0.001% of
the wet weight of marrow-free compact bone.19–21 Before the successful cloning and expression of
recombinant forms of osteoinductive proteins, relatively large amounts of diaphysial cortical (compact)
bone had been required to extract useful amounts of BMP-containing protein aggregates.18 For
example, Wang et al22 estimated a yield of 20 μg of highly purified (300,000-fold) osteoinductive
preparation per 10 kg of bovine bone, and because even highly purified fractions contain a mixture of
osteogenic and nonosteogenic matrix proteins, accurate dose-response relationships had been difficult
to ascertain. Further, osteogenic activity is known to be influenced by nonspecific and specific immune
reactions to these protein aggregates. Thus, the relatively low activity of crude bone extracts had been
attributed to immunogenic but nonosteogenic components of the extract.1
The derivation and expression of cDNA clones of specific BMPs have permitted precise quantitation of
the action of these molecules. Recombinantly produced protein preparations essentially contain

singular molecular species (roughly 90% pure). Consequently, the measures of inductive protein
contained within implants are more exact, and dose-response studies are more valid. Further, because
members of the BMP family of proteins have been highly conserved (genetically consistent) for
approximately 600 million years, they exhibit virtually no species specificity.8,24 Immunogenic
influences on osteogenic activity, consequently, are minimal. Finally, because gene-cloning technology
enables mass production of these proteins, evaluation of a broad spectrum of doses is feasible.
Recent in vivo ectopic bone-forming assays have suggested that volume of early bone formation is
related linearly to dose of recombinant BMP.23 However, efficacy studies in specific applied clinical
models have not shown, above a defined threshold dose, that the rate or quality of clinical success is
related to the actual dose.5
In this study, all sites implanted with rhBMP-2 achieved clinical arthrodesis by 3 months after
implantation. This was true despite a 40-fold variation between the highest and lowest doses tested.
Compared with the results using autogenous iliac bone graft from the previous study (Tables 3,4), all
rhBMP-2-containing implants were associated with clearly superior clinical and radiographic results
(manual testing: all rhBMP-2 conditions greater than autograft, P < 0.001; radiographic testing: all
rhBMP-2 conditions greater than autograft, P < 0.001). Even the lowest dose within this range was
more effective than was iliac crest graft for generating intersegmental fusion within 3 months.
Additional data from the authors' laboratory on two dogs have shown successful clinical fusion with
autogenous iliac crest graft in this model when the animals were maintained for 6 months.15 It appears
that successful intertransverse process fusions occur with autograft in this model, albeit not as rapidly
as compared with rhBMP-2 implants. The differences were particularly significant at the 3-month
timepoint.
Of three dogs implanted with rhBMP-2 that did not satisfy strict radiographic criteria for fusion
(bilateral intertransverse process bridging), two belonged to the lowest two dose groups. Both animals
exhibited unilateral unions. These findings were not statistically significant, and moreover, when
mechanically tested, the fusions obtained in these animals were neither different from other fusions
within these groups nor from fusions obtained with higher doses of rhBMP-2. Combining the data from
this study and previous data with this model, the authors cannot conclude that there are differences in
the rates of clinical and radiographic fusion produced with 58–2300 μg doses of rhBMP-2 (manual
testing, all fused; radiographic testing, P = 0.38). However, the presence of radiographic “failures” with
the lowest doses suggests that the lower end of this range of doses may be approaching the minimum
effective dose. This may be better elucidated with an increased sampling size at these lower doses.
When characterizing the quality of fusion in terms of mechanical stability, no relationship was noted
between fusion stiffness and rhBMP-2 dose in either sagittal, coronal, or axial planes of motion. When
combined with previous data, still no significant relationship between fusion stiffness and dose was
noted (sagittal bending, P = 0.48; coronal bending, P = 0.11; axial torque, P = 0.06). The data again were
compared after mechanical testing results were reassigned to “high dose” (2300 μg), “low dose” (58–
920 μg), autograft, and carrier-only groups. The comparisons are summarized in Table 5. Both high-and
low-dose rhBMP-2 sites had resultant fusions with greater stiffness than did autografted sites in all
planes of motion (axial torque, P < 0.001, P < 0.001; sagittal bending, P < 0.02, P < 0.01; and coronal

bending, P < 0.04, P < 0.02). High-dose implanted sites were not different from low-dose implanted
sites in stiffness to sagittal and coronal bending (P = 0.42, P = 0.19). High-dose sites did exhibit greater
stiffness to axial torque testing compared with low-dose sites (P = 0.03). However, because this was
noted only in one plane of motion and a significant linear relationship was not observed when the
doses were separated, the authors do not believe that these data confirm a qualitative difference in
strength of fusion. Moreover, evidence that there were no differences in cross-sectional new bone
formation between the different dose groups as determined by quantitative CT analysis further argues
that the fusions were similar qualitatively.

Table 5
Histologically, abundant bone formation had been noted in all specimens containing the inductive
protein. No overt qualitative differences in fusion mass associated with the current spectrum of doses
could be detected. Rather vigorous bone formation was seen despite a low rhBMP-2 dose in some
animals, whereas less bone formation was seen occasionally in high-dose implanted sites. In addition,
there was no relationship between the degree of remodeling or the presence of remnant polymer, and
the dose of the inductive protein.
In the previous study, a chronic foreign body response consisting of multinucleated giant cells,
histiocytes, and pyknotic mononuclear round cells was seen in sites that had been implanted with
OPLA carrier only.16 In this study, a low-grade chronic inflammatory response also was noted in several
specimens that contained OPLA with rhBMP-2 but was far less than the reaction observed when OPLA
was used alone. Interestingly, the inflammatory response to the composite implant inversely was
proportional to the abundance of the fusion mass and not to the dose of the rhBMP-2. It is possible
that this is related to a limited population of inducible stem cells. Thus, rapid recruitment of stem cells
to boneforming cells may limit the number of cells available for an inflammatory response. Conversely,

the presence of an early inflammatory response may limit the number of stem cells available for
osteoinduction, thereby altering subsequent osteogenesis. Stem cell lineage studies currently are in
progress and may provide useful information in the near future.
The events of the biologic response to rhBMP-2 in vivo are complex and may be influenced by several
variables. The timecourse of activity of rhBMP-2 in the bone formation process, the location of its
target cell, and its interactions with other growth factors are subjects of current research.11,12,18
Certainly, the influence of the delivery vehicle cannot be overemphasized. Osteoinductive molecules
such as rhBMP-2, when implanted alone, are cleared rapidly from the circulation and are ineffective.
Lucas et al10 and other have suggested that optimal delivery of inductive proteins requires controlled
release, adequate exposure of the protein to the inducible target cells, ease of ingrowth of host tissue
into the carrier, biocompatibility of the carrier, and resorption or incorporation of the implant into
newly formed bone.
An open-cell polylactic acid polymer was used exclusively as the delivery vehicle in this study. The
measured efficacy of rhBMP-2 in this model, consequently, is a reflection of this carrier's ability to
satisfy the previously mentioned requirements. Biocompatibility of polylactic acid polymers has been
of concern in previous studies,7,13,14 and the presence of an immune response could be expected to
influence the activity of the inductive protein. A prominent foreign body reaction was noted in the
previous study when the polymeric delivery vehicle was implanted alone and was subdued in this study
when the carrier was combined with the osteoinductive protein. The effect of even the low-grade
inflammatory processes on the osteoinductivity of rhBMP-2 is unresolved. A similar relation between
efficacy and dose would not necessarily be observed if another delivery vehicle such as fibrillar
collagen, insoluble noncollagenous protein, or biocompatible ceramic were used. This model currently
is being used to investigate some of these alternative delivery vehicles.
There is some evidence, although inconclusive, that more evolved animals may have a relative lack of
inducible cells outside the skeleton.2 The activity of rhBMP-2 in nonhuman primates currently is the
subject of considerable interest. In this regard, it remains to be seen whether dosing data gathered
from lower vertebrate models such as this can be appropriately extrapolated for use in humans.
Nonetheless, the intent of this investigation was to characterize the relation between dosage of
rhBMP-2 and clinical efficacy in an applied spinal fusion model. Previous studies on long bone defects
in lower vertebrate models have suggested that, above a minimal threshold dose, the clinical
effectiveness of rhBMP-2 remains relatively consistent. In this study, the similarity of the fusions
obtained across a 40-fold range of doses suggests that such a relationship may exist for dog spinal
fusions.

Conclusion
Above a minimum threshold dose, fusions produced in lower vertebrates with recombinant
osteoinductive morphogens, such as rhBMP-2, do not vary with increasing dose. Variables such as the
delivery vehicle, surgical technique, and evolutionary status of the recipient may be more pertinent.
Further studies examining these factors would be beneficial.
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